by Raynovich Rod | Apr 17, 2013 | Biopharmaceuticals, Macro
Major Sell-Off Early On April 17–Correction is Here with Some Technical Damage Posted 12.15p EDT, Update at 4:56p The rally yesterday was apparently a head fake as a major sell-off resumed today with the NASDAQ down 2.10% and the S&P down 1.7%. The gold free...
by Raynovich Rod | Apr 15, 2013 | 2025 Rayno Biopharmaceuticals Portfolio, BIOgraph, Clinical Diagnostics and Tools, Macro
Gold Crash Spooks Traders-Life Science Stocks Lose Resilience IBB ($166.82) Down 1.6% Rayno Life Science Stocks- Quick Look With NAZ at 2343 We have not made any Rayno Portfolio changes but have added two stocks recently: Genomic Health (GHDX) and Hologic (HOLX) both...
by Raynovich Rod | Apr 12, 2013 | 2025 Rayno Biopharmaceuticals Portfolio, Macro
Biotech and Drug Stocks Remain in the Sweet Spot NAZ Down 0.16% at 3295 at Close A string of market up days was halted today as retail sales and consumer sentiment gave bearish indicators.Commodity stocks were also weak-energy down 1.2%, materials down 1.7%- and there...
by Raynovich Rod | Apr 10, 2013 | Biopharmaceuticals, Clinical Diagnostics and Tools
Life Science Stocks Blow Through New Highs The Rayno Biopharma stocks continued their run today and some Tools/DX stocks are freshening up. Yesterday we added Hologic (HOLX) as a turnaround/value play and it is up 1.73%. Other Rayno winners in this lagging sector...
by Raynovich Rod | Apr 4, 2013 | 2025 Rayno Biopharmaceuticals Portfolio, BIOgraph, Macro
Biotechnology Sector Q2 2013- At All Time Highs The BTK and ETFs such as the IBB and XBI hit all time highs on April 2. Of course the current ramp cannot go on forever because money moves on, speculation ebbs and math intervenes. We have been picking biotech stocks...
by Raynovich Rod | Mar 28, 2013 | 2024-25 Life Science Portfolios, Biopharmaceuticals
Rayno Life Science Stocks Having A Nice Q1 Ending Run Well known Large Caps Dominate Rayno focus stocks that are running up 2% + today: AMGN, AMRI, ASTX, BIIB, GILD, QGEN, and REGN. The Biopharma sector is outperforming Tools and Dx for Q1. Tools and DX winners for...
by Raynovich Rod | Mar 22, 2013 | BIOgraph, Biopharmaceuticals
Rayno Biopharmaceutical Stocks In a Stealth Rally-Most Core Positions Up No changes have been made in core portfolio positions except as noted below. See update in Seeking Alpha. Action today with strong charts since Feb 26 Sell-Off ALXN ($93) stable and recovering...
by Raynovich Rod | Mar 14, 2013 | Biopharmaceuticals, Macro
Technicals Matter in a MOmentum Market Some important trends are developing in momentum stocks some of which are on in our Life Science Portfolio. As we have written previously many momentum stocks are being driven by media buzz, novel business models and sponsorship...
by Raynovich Rod | Mar 5, 2013 | 2025 Rayno Biopharmaceuticals Portfolio, Macro
FED Fuel Fans Feuer The monetized momentum market rolled on today despite the backdrop of bearish commentary from celebrity pundits and strategists. With the DOW hitting new highs at 14,263 (and forgetting about the 2001 NASDAQ 5000 high which is still 2000 points...
by Raynovich Rod | Mar 4, 2013 | BIOgraph, Biopharmaceuticals
Biotech Rally Takes Sector to New Highs After a brief lull many biopharmaceuticals stocks are rallying over 2% today. Recently we reiterated Cubist (CBST $45.38) up 4.4% and Optimer (OPTR $12.62) up 3.34% and both are among big movers today. Taking the lead from some...
